Patents Examined by Jane J Zara
  • Patent number: 11981896
    Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: May 14, 2024
    Assignee: 1E Therapeutics Ltd.
    Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • Patent number: 11981898
    Abstract: The present disclosure provides compositions and methods for targeted insertion of a gene of interest in the genome of a cell using single-stranded DNA or double-stranded DNA with 3 overhang. Also provided are methods of generating single-stranded DNA or double-stranded DNA with 3? over-hang that can be used for targeted insertion.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: May 14, 2024
    Assignee: APPLIED STEMCELL, INC.
    Inventors: Lingjie Kong, Alfonso Farruggio, Andrew Hilmer, Padmaja Tummala, Ruby Yanru Tsai
  • Patent number: 11959143
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 16, 2024
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • Patent number: 11958888
    Abstract: Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: April 16, 2024
    Assignee: University of Washington
    Inventors: Jeffrey S. Chamberlain, Julian Ramos, Stephen D. Hauschka
  • Patent number: 11957704
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: April 16, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Patent number: 11944676
    Abstract: Generally, the inventive technology relates to novel strategies for disease control in animal systems. Specifically, the inventive technology relates to novel methods, systems and compositions for the biocontrol of pathogens in aquatic systems. Specifically, the invention may comprise novel techniques, systems, and methods for the biocontrol of disease-transmitting pathogens affecting shrimp in aquaculture systems.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 2, 2024
    Assignee: Pebble Labs Inc.
    Inventors: Richard Sayre, Tatiana Vinogradova-Shah, Elena Sineva
  • Patent number: 11939576
    Abstract: The present invention provides non-propagating transgenic microalgae expressing at least one heterologous RNAi molecule. The RNAi-expressing non-propagating transgenic microalgae are used for oral delivery of the RNAi molecule to a target organism in its intact and functional form. The heterologous RNAi molecule, present within the microalgae, is characterized by being biologically active, exerting at least one specific effect on the organism consuming the microalgae or on a pathogen of said organism. In particular, the non-propagating transgenic microalgae are used as agents for biological control of animal and plant pests.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: March 26, 2024
    Assignee: TRANSALGAE ISRAEL LTD.
    Inventor: Ofra Chen
  • Patent number: 11939577
    Abstract: The present invention relates to antisense RNAs targeting PMP22 and able to inhibit from 40% to 60% the expression of PMP22 in the cells and a pharmaceutical composition comprising thereof. The antisense RNAs are preferably siRNA and are preferably provided in the form of nanoparticles. The present invention also relates to the use of these antisense RNAs targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: March 26, 2024
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Liliane Massade, Charbel Massaad, Susan Boutary, Giorgia Maria Laura Urbinati, Patrick Couvreur, Didier Desmaële
  • Patent number: 11938187
    Abstract: The syntheses of two phosphoramidite building blocks based on BNSF and BNSMB structures are disclosed. Furthermore, some common molecular intermediates have been designed and linked to the central biphenyl core of the two molecules, resulting in a versatile and cost-effective design. These compounds can be effectively introduced to DNA oligonucleotides via the well-established standard cyanoethylphosphoramidite chemistry on the nucleic acid synthesizer. Fragmentation of these BNSF- and BNSMB-functionalized DNA strands is achieved by both one-photon and two-photon photolysis of photoliable bonds of [2-(2-nitrophenyl)propoxy]carbonyl groups on BNSF and BNSMB molecules respectively, resulting in two short pieces of single-stranded DNAs.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: March 26, 2024
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventors: Peggy Pik Kwan Lo, Ling Sum Liu, Dick Yan Tam
  • Patent number: 11926824
    Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: March 12, 2024
    Assignees: Board of Regents, The University of Texas System, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Raghu Kalluri, Sónia Melo
  • Patent number: 11912999
    Abstract: An aptamer-N-heterocyclic-carbene metal complex conjugate (aptamer-NHCM conjugate) or an aptamer-bis-N-heterocyclic-carbene metal complex conjugate (aptamer-bis-NHCM conjugate) includes an aptamer coupled through a hydrolytically stable bond to an N-heterocyclic-carbene metal complex (NHCM) or a bis-N-heterocyclic-carbene metal complex (bis-NHCM). The aptamer-NHCM conjugate is prepared where the chosen aptamer displays selective binding to a cell specific receptor, such that the cytotoxic NHCM can be directed specifically to cells responsible for a target disease (e.g., a specific cancer type). A method of preparing the aptamer-N-heterocyclic-carbene metal complex conjugate involves installing a coupling group to an N-heterocyclic-carbene metal complex that can specifically bond with a functional group on an aptamer; the bond, covalent or non-covalent, is stable hydrolytically in the absence of an environment that promotes intentional cleavage of the bond.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: February 27, 2024
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Adam S. Veige, Mary E. Garner, Weijia Niu
  • Patent number: 11896606
    Abstract: The present invention relates to compositions comprising particles, each of the respective particles comprising particles formed by polyribonucleotides and polymers. Specifically, the composition comprises a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(I:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to methods of manufacturing the compositions, and further to related pharmaceutical compositions useful for the treatment of any cell growth disorder characterized by an abnormal growth of human or animal cells.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: February 13, 2024
    Assignee: Highlight Therapeutics, S.L.
    Inventors: Mercedes Pozuelo Rubio, Marisol Quintero Ortiz, Ana Villanueva Garcia
  • Patent number: 11896669
    Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: February 13, 2024
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Matthew Hassler, Julia Alterman, Bruno Miguel da Cruz Godinho
  • Patent number: 11884921
    Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods provide signal boost upon detection of target nucleic acids of interest in less than one minute and in some instances instantaneously at ambient temperatures down to 16° C. or less, without amplification of the target nucleic acids yet allowing for massive multiplexing, high accuracy and minimal non-specific signal generation.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: January 30, 2024
    Assignee: VedaBio, Inc.
    Inventors: Anurup Ganguli, Ashish Pandey, Ariana Mostafa, Jacob Berger
  • Patent number: 11883424
    Abstract: The present invention relates to compositions comprising complexes that are formed by polyinosinic-polycytidylic acid with a polyalkyleneimine, such as polyethyleneimine, that present uniform structural and functional features, as well as to methods for preparing the compositions that comply with regulatory requirements. The present invention additionally relates to use of said compositions as medicaments (in particular for treating cancer), alone or in combination with other therapeutic agents and/or in specific medical methods. Moreover, the administration of these compositions is associated to changes in the expression of specific genes, in cell responses, and/or in composition of immune cell populations that can be used as specific biomarkers and/or as additional target for medical treatment.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: January 30, 2024
    Assignee: Highlight Therapeutics, S.L.
    Inventors: Marisol Quintero Ortiz, Mercedes Pozuelo Rubio, Lourdes Planelles Carazo
  • Patent number: 11878991
    Abstract: Provided herein are methods and compositions for synthesizing 5?Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N2?Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: January 23, 2024
    Assignee: TriLink BioTechnologies, LLC
    Inventors: Richard I. Hogrefe, Alexandre Lebedev, Anton P. McCaffrey, Dongwon Shin
  • Patent number: 11879126
    Abstract: Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.
    Type: Grant
    Filed: October 20, 2022
    Date of Patent: January 23, 2024
    Assignee: Nutcracker Therapeutics, Inc.
    Inventors: Samuel Deutsch, Daniel Frimannsson, Nicole Fay, Colin McKinlay, Ole Haabeth
  • Patent number: 11873493
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: January 16, 2024
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 11872290
    Abstract: The present invention relates to a bicistronic expression vector for silencing a gene specifically in astrocytes and neurons, comprising two expression cassettes comprising a first and a second silencer sequence, respectively, wherein the expression of said first silencer sequence within astrocytes is regulated by an astrocyte-specific promoter and the expression of said second silencer sequence within neurons is regulated by a neuron-specific promoter. In a preferred embodiment, said first and second silencer sequences are SOD1 silencer sequences. Pharmaceutical composition comprising said bicistronic vector and the use of the same in the treatment of motoneuron diseases are further described.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: January 16, 2024
    Assignee: Ecole Polytechnique Federale De Lausanne (EPFL)
    Inventors: Julianne Aebischer, Bernard Schneider, Cylia Rochat
  • Patent number: 11872239
    Abstract: The present invention relates to a composition comprising an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides and one or more lipid moiety, wherein said one or more lipid moiety is covalently linked to said oligomeric compound either directly or via a spacer, and wherein preferably said oligomeric compound comprises from 5 to 40 monomer subunits, as well as pharmaceutical compositions thereof and their uses in the prevention or treatment of neuromuscular or musculoskeletal diseases such as Duchenne muscular dystrophy or Steinert disease.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: January 16, 2024
    Assignee: Synthena AG
    Inventors: Wolfgang Andreas Renner, Branislav Dugovic, Reto Bertolini